Disruption of VEGF signaling and tumor angiogenesis using soluble VEGFR, VEGF high-affinity binding chimeras, anti-VEGF monoclonal antibodies (e.g., bevacizumab), and ribozymes have shown strong antitumor activity in PDAC mouse xenografts and cultured pancreatic cancer cell lines (Hezel et al., 2006; Koorstra et al., 2008). The gene discussed is VEGFA; the disease is neoplasm.